Life Sciences

AGG's Life Sciences attorneys have worked with emerging and established life sciences companies for more than a quarter of a century. Group members include attorneys experienced in navigating the unique financial, technical and regulatory challenges facing life sciences companies. Our attorneys have assisted life sciences clients from start-up through listing on the New York Stock Exchange. Combining our legal, business and scientific experiences, we work closely with medical device, biologics and pharmaceutical companies in taking new ideas through the challenges of product development, intellectual property protection, funding, premarket approval, licensing, commercialization and regulatory compliance. We have assisted clients in private and public fundraising, mergers, acquisitions, divestitures, strategic partnerings and joint ventures.

Our group includes representatives from other complementary AGG practice groups - Growth Companies, Food and Drug, Intellectual Property and Healthcare - and draws from the full array of expertise available at the firm. Our resident capabilities include attorneys who have advised medical device and drug companies in FDA regulatory and compliance matters for more than 25 years, attorneys experienced in international regulatory issues spawned by clients’ overseas expansion, attorneys skilled in Medicare and Medicaid reimbursement strategies, and attorneys knowledgeable in environmental regulatory issues. Group attorneys have counseled biotech start-ups and spin-offs, completed private and public fundings for device and pharmaceutical companies and structured licenses and development agreements for new life sciences technologies. By combining our expertise in these and other areas vital to success in the life sciences industry, we offer emerging and established life sciences companies a valuable resource to support their growth and development.

News & Events > Alan Minsk spoke at the Change Control for Biopharmaceutical Manufacturing seminar March 10-11, his topic "Examine the FDA's Inspectional Authority and Enforcement Tools for Change Control." > Alan Minsk was quoted in an Atlanta Business Chronicle article titled "Ga. Medical Device Business Growing" on October 24. > Alan Minsk spoke at CBI’s 4th Annual Guidelines for Disseminating Off-Label Information on October 21-22. > AGG sponsored the Southeast-Israel Medical Technology Business Exchange on October 13-15. > Alan Minsk spoke at the LabMation 2002 Conference, September 30-October 2. > Read summaries of select bills related to Life Sciences from the 2002 Georgia Legislature Session Publications > Articles - Privacy in the Information Age, Home Health Products > Final Compliance Program Guidance for Pharmaceutical Manufacturers - May 2003

Representative Clients > > > > CryoLife CIBA Vision Corp. First Horizon Pharmaceutical King Pharmaceuticals, Inc.

Related Practice Areas > > > > Food and Drug Growth Companies Healthcare HIPAA Compliance